Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKYGet Free Report) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 800 shares, a decrease of 50.0% from the February 13th total of 1,600 shares. Based on an average trading volume of 559,900 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Daiichi Sankyo Stock Down 2.7 %

Shares of OTCMKTS DSNKY opened at $23.12 on Friday. The firm has a market cap of $44.12 billion and a PE ratio of 26.88. The company has a 50 day simple moving average of $25.34 and a 200 day simple moving average of $30.01. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.77 and a quick ratio of 2.11. Daiichi Sankyo has a 1 year low of $22.47 and a 1 year high of $42.48.

Daiichi Sankyo (OTCMKTS:DSNKYGet Free Report) last posted its earnings results on Friday, January 31st. The company reported $0.22 earnings per share for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. On average, research analysts forecast that Daiichi Sankyo will post 0.73 EPS for the current year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.

Featured Articles

Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.